Whitnell & Co. Has $3.68 Million Holdings in Johnson & Johnson (JNJ)
Whitnell & Co. raised its position in Johnson & Johnson (NYSE:JNJ) by 0.2% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 27,815 shares of the company’s stock after buying an additional 51 shares during the period. Johnson & Johnson makes up about 1.6% of Whitnell & Co.’s holdings, making the stock its 17th biggest holding. Whitnell & Co.’s holdings in Johnson & Johnson were worth $3,680,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of JNJ. Lenox Wealth Advisors Inc. boosted its position in Johnson & Johnson by 0.6% in the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after buying an additional 5 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. raised its stake in shares of Johnson & Johnson by 241.0% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock valued at $149,000 after purchasing an additional 841 shares in the last quarter. Ullmann Financial Group Inc. acquired a new stake in shares of Johnson & Johnson in the 1st quarter valued at about $186,000. Taylor Wealth Management Partners raised its stake in shares of Johnson & Johnson by 19.8% in the 1st quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock valued at $188,000 after purchasing an additional 250 shares in the last quarter. Finally, Puplava Financial Services Inc. acquired a new stake in shares of Johnson & Johnson in the 2nd quarter valued at about $202,000. 66.06% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “Whitnell & Co. Has $3.68 Million Holdings in Johnson & Johnson (JNJ)” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/11/08/whitnell-co-has-3-68-million-holdings-in-johnson-johnson-jnj.html.
A number of brokerages have recently issued reports on JNJ. Credit Suisse Group restated a “buy” rating on shares of Johnson & Johnson in a research note on Friday, August 4th. Piper Jaffray Companies reiterated a “hold” rating and set a $120.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 4th. Vetr lowered shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 price objective on the stock. in a research note on Monday, September 18th. Alembic Global Advisors lowered shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating in a research note on Friday, July 21st. Finally, Stifel Nicolaus increased their price objective on shares of Johnson & Johnson from $140.00 to $142.00 and gave the stock a “hold” rating in a research note on Wednesday, October 18th. Four equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the stock. Johnson & Johnson currently has a consensus rating of “Hold” and a consensus price target of $143.70.
Johnson & Johnson (NYSE JNJ) opened at $139.77 on Wednesday. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. The stock has a market cap of $374,640.00, a P/E ratio of 19.62, a PEG ratio of 2.85 and a beta of 0.82. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $144.35.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.80 by $0.10. The business had revenue of $19.65 billion during the quarter, compared to analysts’ expectations of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business’s revenue was up 10.3% on a year-over-year basis. During the same period last year, the firm posted $1.68 earnings per share. analysts anticipate that Johnson & Johnson will post 7.28 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be issued a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 2.40%. The ex-dividend date is Monday, November 27th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 58.33%.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.